http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 07:00:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html <p>Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway (datopotamab deruxtecan) as an adjuvant treatment for patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection.</p> <p>The global, multicenter, open-label trial will enroll approximately 915 patients across sites in Asia, Europe, North America, Oceania and South America. Patients will be randomized in a 2:1:2 ratio to receive Datroway in combination with rilvegostomig, Datroway as a monotherapy, or current standard of care, which includes durvalumab monotherapy, nivolumab monotherapy, or enfortumab vedotin plus pembrolizumab.</p> <p>The primary http://www.streetinsider.com/FDA/Daiichi+Sankyo+and+AstraZeneca+start+phase+3+urothelial+cancer+trial/26977185.html Wed, 26 Aug 2026 07:00:26 -0400 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html <p> TOKYO--(BUSINESS WIRE)-- The first patient has been dosed in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07720284&amp;esheet=54594418&amp;newsitemid=20260825228143&amp;lan=en-US&amp;anchor=TROPION-Urothelial04&amp;index=1&amp;md5=9a6bb3624f4e348abfa92a61756003d7" shape="rect">TROPION-Urothelial04</a> phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. </p><p> Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html Wed, 26 Aug 2026 07:00:00 -0400 4568 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN AZN CGEN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html <p> TOKYO--(BUSINESS WIRE)-- The first patient has been dosed in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07720284&amp;esheet=54594418&amp;newsitemid=20260825228143&amp;lan=en-US&amp;anchor=TROPION-Urothelial04&amp;index=1&amp;md5=9a6bb3624f4e348abfa92a61756003d7" shape="rect">TROPION-Urothelial04</a> phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. </p><p> Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html Wed, 26 Aug 2026 07:00:00 -0400 4568 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN AZN CGEN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html <p> TOKYO--(BUSINESS WIRE)-- The first patient has been dosed in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07720284&amp;esheet=54594418&amp;newsitemid=20260825228143&amp;lan=en-US&amp;anchor=TROPION-Urothelial04&amp;index=1&amp;md5=9a6bb3624f4e348abfa92a61756003d7" shape="rect">TROPION-Urothelial04</a> phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. </p><p> Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html Wed, 26 Aug 2026 07:00:00 -0400 4568 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN AZN CGEN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html <p> TOKYO--(BUSINESS WIRE)-- The first patient has been dosed in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07720284&amp;esheet=54594418&amp;newsitemid=20260825228143&amp;lan=en-US&amp;anchor=TROPION-Urothelial04&amp;index=1&amp;md5=9a6bb3624f4e348abfa92a61756003d7" shape="rect">TROPION-Urothelial04</a> phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. </p><p> Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html Wed, 26 Aug 2026 07:00:00 -0400 4568 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN AZN CGEN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150 http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html <p> TOKYO--(BUSINESS WIRE)-- The first patient has been dosed in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07720284&amp;esheet=54594418&amp;newsitemid=20260825228143&amp;lan=en-US&amp;anchor=TROPION-Urothelial04&amp;index=1&amp;md5=9a6bb3624f4e348abfa92a61756003d7" shape="rect">TROPION-Urothelial04</a> phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. </p><p> Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo http://www.streetinsider.com/Press+Releases/TROPION-Urothelial04+Phase+3+Trial+of+Datroway%C2%AE+Initiated+as+Adjuvant+Therapy+in+Patients+with+High-Risk+Muscle+Invasive+Urothelial+Cancer/26977150.html Wed, 26 Aug 2026 07:00:00 -0400 4568 4568 A.06822034 A.15882755 A.17568957 A.28611341 A.42377854 A.60001765 AZN AZN CGEN CGEN DSNKY O.00043880 O.00436461 O.00653212 O.01918044 O.04889877 O.17791244 O.20026344 O.20738543 O.22492915 O.28886150